2-Thiocytidin-5'-phosphat | 36238-43-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 2-Thiocytidin-5'-phosphat
• 英文别名: 2-thio-[5']cytidylic acid；Thiocytidylate；[(2R,3S,4R,5R)-5-(4-amino-2-sulfanylidenepyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 36238-43-4
• 化学式: C₉H₁₄N₃O₇PS
• 分子量: 339.266
• InChiKey: BPWVHBCPZTVLLY-XVFCMESISA-N

物化性质

• 沸点：
  670.4±65.0 °C(Predicted)
• 密度：
  2.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  157
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• Method of producing nucleic acid molecules with reduced secondary structure
  申请人：Agilent Technologies, Inc.

  公开号：EP1624059A2

  公开（公告）日：2006-02-08

  The present invention provides a system for generating nucleic acid molecules having a reduced ability to hybridize to form intermolecular and intramolecular base pairs between regions of substantial complementarity as compared with nucleic acid molecules having the same nucleotide sequence containing naturally-occurring nucleotides. Furthermore, nucleic acid molecules of the present invention are characterized by the ability to form intermolecular base pairs with other nucleic acid molecules of choice.

  本发明提供了一种生成核酸分子的系统，与具有相同核苷酸序列、含有天然存在的核苷酸的核酸分子相比，本发明的核酸分子具有较低的杂交能力，能够在具有实质性互补性的区域之间形成分子间和分子内碱基对。此外，本发明核酸分子的特点是能够与所选择的其他核酸分子形成分子间碱基配对。
• DRUG CARRIER
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2292270A1

  公开（公告）日：2011-03-09

  A drug carrier characterized by mainly containing a polyethylene-glycol-modified phospholipid and a cationic lipid and containing the polyethylene-glycol-modified phospholipid in a concentration within a specific range. The drug carrier, which is of the in-blood residence type, is characterized by comprising a polyethylene-glycol-modified phospholipid represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein X represents the following (II) or (III) and n is an integer of 30-150] [wherein R1 represents a saturated linear C17-22 fatty acid residue] and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-0-dioleoylglylcerol. It is further characterized in that the polyethylene-glycol-modified phospholipid represented by the general formula (I) is contained in an amount of 30-50 wt.% based on the total amount of the lipids in the drug carrier.

  一种药物载体，其特征在于主要含有聚乙二醇改性磷脂和阳离子脂质，且聚乙二醇改性磷脂的浓度在特定范围内。该药物载体属于血内滞留型，其特征在于包含由以下通式（I）代表的聚乙二醇改性磷脂或其药学上可接受的盐： [其中 X 代表下式（II）或（III），n 为 30-150 的整数］ [其中 R1 代表饱和线性 C17-22 脂肪酸残基]和 2-O-(2-二乙基氨基乙基)氨基甲酰基-1,3-0-二油酰甘油。其进一步特征在于，通式(I)所代表的聚乙二醇改性磷脂的含量为药物载体中脂类总量的 30-50wt.%。
• Method of examining efficacy of therapy with nucleic acid
  申请人：——

  公开号：US20030125285A1

  公开（公告）日：2003-07-03

  The present invention provides a method of examining efficacy of treatment with a nucleotide or a nucleoside having antitumor- or antivirus activity in individual patients beforehand, which method is mainly connected to tailor-made therapy, a method of screening for agents potentially having antitumor or antivirus activity, and method of investigating the mechanism of action of an antitumor or antivirus agent in vivo.

  本发明提供了一种事先检查具有抗肿瘤或抗病毒活性的核苷酸或核苷类药物对个体患者的疗效的方法，该方法主要与定制疗法有关，还提供了一种筛选可能具有抗肿瘤或抗病毒活性的药剂的方法，以及研究抗肿瘤或抗病毒药剂在体内的作用机制的方法。
• HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION
  申请人：Stratos Genomics Inc.

  公开号：EP2171088A2

  公开（公告）日：2010-04-07
• US7939259B2
  申请人：——

  公开号：US7939259B2

  公开（公告）日：2011-05-10